Certara (NASDAQ:CERT) Given New $12.00 Price Target at Barclays

Certara (NASDAQ:CERT) had its price target lifted by Barclays from $9.00 to $12.00 in a research report sent to investors on Friday,Benzinga reports. They currently have an equal weight rating on the stock.

Other research analysts have also recently issued reports about the company. UBS Group reaffirmed a “neutral” rating and set a $13.00 price objective on shares of Certara in a research report on Friday. Weiss Ratings lowered shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. TD Cowen raised their target price on shares of Certara from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Finally, KeyCorp upped their price target on shares of Certara from $9.00 to $12.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.92.

Certara Stock Performance

CERT traded down $0.13 during trading on Friday, hitting $12.05. The company’s stock had a trading volume of 4,871,054 shares, compared to its average volume of 2,550,419. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. Certara has a one year low of $4.45 and a one year high of $12.61. The firm has a market cap of $1.84 billion, a PE ratio of -28.69 and a beta of 1.30. The business’s 50 day simple moving average is $9.33 and its 200-day simple moving average is $7.35.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.09 earnings per share for the quarter, hitting the consensus estimate of $0.09. The business had revenue of $94.90 million for the quarter, compared to analysts’ expectations of $92.01 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The company’s revenue was down 9.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.14 EPS. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. As a group, sell-side analysts predict that Certara will post 0.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Certara in the 2nd quarter worth approximately $123,259,000. Haveli Investment Management LLC bought a new stake in shares of Certara during the second quarter valued at approximately $48,470,000. Jefferies Financial Group Inc. bought a new stake in shares of Certara during the second quarter valued at approximately $46,446,000. Bank of America Corp DE purchased a new position in shares of Certara in the second quarter worth $11,780,000. Finally, Tejara Capital Ltd purchased a new position in shares of Certara in the second quarter worth $8,467,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Certara

Here are the key news stories impacting Certara this week:

• Positive Sentiment: Certara raised its 2026 revenue outlook to $427.2 million–$431.4 million, well above the cited analyst consensus of $380.9 million. Its EPS guidance of $0.31–$0.34 also met or exceeded the $0.31 consensus midpoint, giving investors a stronger forward outlook. Article: Certara Q3 2026 Earnings Call Highlights
• Positive Sentiment: Third-quarter revenue of $94.9 million topped the $92.0 million consensus, while EPS was reported at $0.09, meeting some estimates and exceeding others. Reports also highlighted double-digit software revenue growth—the first such pace in two years—which helped support a positive share-price reaction after the update. Article: Certara Q3 2026 earnings
• Neutral Sentiment: Barclays raised its price target from $9 to $12 but kept an Equal Weight rating, signaling improved valuation expectations without a bullish call. Article: Barclays price target update
• Negative Sentiment: UBS downgraded CERT from Buy to Neutral, though its $13 price target remains above the price cited in the report. The downgrade may restrain enthusiasm after the stock’s recent rally. Article: UBS downgrades Certara

About Certara

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.